TISIDB

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF13405 EF-hand domain PF13833 EF-hand domain pair
Function	Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion.

> Gene Ontology [ TOP ]
Biological Process	GO:0003012 muscle system process GO:0006936 muscle contraction GO:0006937 regulation of muscle contraction GO:0007596 blood coagulation GO:0007599 hemostasis GO:0030168 platelet activation GO:0034109 homotypic cell-cell adhesion GO:0044057 regulation of system process GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0070527 platelet aggregation GO:0090257 regulation of muscle system process
Molecular Function	GO:0008307 structural constituent of muscle GO:0017022 myosin binding GO:0032036 myosin heavy chain binding
Cellular Component	GO:0001725 stress fiber GO:0005859 muscle myosin complex GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0016460 myosin II complex GO:0030016 myofibril GO:0030017 sarcomere GO:0030018 Z disc GO:0031674 I band GO:0032432 actin filament bundle GO:0042641 actomyosin GO:0043292 contractile fiber GO:0044449 contractile fiber part GO:0097517 contractile actin filament bundle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04022 cGMP-PKG signaling pathway hsa04024 cAMP signaling pathway hsa04270 Vascular smooth muscle contraction hsa04510 Focal adhesion hsa04530 Tight junction hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton hsa04921 Oxytocin signaling pathway
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928663: EPHA-mediated growth cone collapse R-HSA-397014: Muscle contraction R-HSA-195258: RHO GTPase Effectors R-HSA-5627117: RHO GTPases Activate ROCKs R-HSA-5625900: RHO GTPases activate CIT R-HSA-5627123: RHO GTPases activate PAKs R-HSA-5625740: RHO GTPases activate PKNs R-HSA-400685: Sema4D in semaphorin signaling R-HSA-416572: Sema4D induced cell migration and growth-cone collapse R-HSA-373755: Semaphorin interactions R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-445355: Smooth Muscle Contraction

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04510 Focal adhesion
hsa04530 Tight junction
hsa04670 Leukocyte transendothelial migration
hsa04810 Regulation of actin cytoskeleton
hsa04921 Oxytocin signaling pathway

Reactome

R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-397014: Muscle contraction
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627117: RHO GTPases Activate ROCKs
R-HSA-5625900: RHO GTPases activate CIT
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-400685: Sema4D in semaphorin signaling
R-HSA-416572: Sema4D induced cell migration and growth-cone collapse
R-HSA-373755: Semaphorin interactions
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-445355: Smooth Muscle Contraction

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYL9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYL9 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYL9 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.03	0.0271
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.099	0.708
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.967	0.622
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.597	0.487
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.696	0.803
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.471	0.895
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.3	0.585
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.842	0.614
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.329	0.862
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.126	0.669
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2	0.6
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.32	0.0843

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYL9 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYL9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYL9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYL9. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYL9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYL9 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYL9 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYL9
Name	myosin, light chain 9, regulatory
Aliases	MYRL2; LC20; MRLC1; myosin regulatory light chain 2, smooth muscle isoform; myosin regulatory light chain 1; ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYL9 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYL9